Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 4/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | AR | P10275 | 3/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.35 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.35 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | VDR | P11473 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL116799 | 1.00 | MAPK1 (0.56) | MAPK1LMNAALDH1A1USP2AR | |
| SCHEMBL8083397 | 1.00 | MAPK1 (0.56) | MAPK1LMNAALDH1A1USP2AR | |
| Hydrochloric Acid SCHEMBL8201302 | 0.97 | MAPK1 (0.54) | MAPK1LMNAALDH1A1USP2AR | |
| SCHEMBL1982314 | 0.86 | MAPK1 (0.65) | MAPK1ALDH1A1KDM4ETSHRTDP1 | |
| SCHEMBL6269634 | 0.84 | LMNA (0.40) | MAPK1LMNAALDH1A1USP2AR | |
| SCHEMBL6034519 | 0.82 | LMNA (0.38) | MAPK1LMNAALDH1A1USP2AR | |
| SCHEMBL9309371 | 0.81 | MAPK1 (0.59) | MAPK1ALDH1A1USP2KDM4EMEN1 | |
| SCHEMBL9965260 | 0.81 | MAPK1 (0.39) | MAPK1USP2ARVDR | |
| SCHEMBL14901102 | 0.79 | MAPK1 (0.56) | MAPK1ALDH1A1KDM4ETSHRTDP1 | |
| SCHEMBL2609782 | 0.79 | MAPK1 (0.56) | MAPK1ALDH1A1KDM4ETSHRTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9388112-B2 | Bisphenol derivatives and their use as androgen receptor activity modulators | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2016-07-12 | — | — | US | disclosed |
| US-9206174-B2 | 5-anilinoimidazopyridines and methods of use | GENENTECH, INC. (US) | 2015-12-08 | — | — | US | disclosed |
| US-9206174-B2 | 5-anilinoimidazopyridines and methods of use | GENENTECH, INC. (US) | 2015-12-08 | — | — | US | disclosed |
| US-8841462-B2 | Bicyclic heterocycles as MEK kinase inhibitors | GENENTECH, INC. | 2014-09-23 | — | — | US | disclosed |
| US-8841462-B2 | Bicyclic heterocycles as MEK kinase inhibitors | GENENTECH, INC. | 2014-09-23 | — | — | US | disclosed |
| US-20140248263-A1 | BISPHENOL COMPOUNDS AND METHODS FOR THEIR USE | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2014-09-04 | — | — | US | disclosed |
| US-8492427-B2 | Isoindolones derivatives as MEK kinase inhibitors and methods of use | GENENTECH, INC. (US) | 2013-07-23 | — | — | US | disclosed |
| US-8492427-B2 | Isoindolones derivatives as MEK kinase inhibitors and methods of use | GENENTECH, INC. (US) | 2013-07-23 | — | — | US | disclosed |
| US-8486963-B2 | Azaindolizines and methods of use | GENENTECH, INC. (US) | 2013-07-16 | — | — | US | disclosed |
| US-8486963-B2 | Azaindolizines and methods of use | GENENTECH, INC. (US) | 2013-07-16 | — | — | US | disclosed |
| US-20100216768-A1 | N-SUBSTITUTED AZAINDOLES AND METHODS OF USE | GENENTECH, INC. | 2010-08-26 | — | — | US | disclosed |
| US-20100004269-A1 | 5-ANILINOIMIDAZOPYRIDINES AND METHODS OF USE | GENENTECH, INC. (US) | 2010-01-07 | — | — | US | disclosed |
| US-20100004269-A1 | 5-ANILINOIMIDAZOPYRIDINES AND METHODS OF USE | GENENTECH, INC. (US) | 2010-01-07 | — | — | US | disclosed |
| US-20090312559-A1 | CATALYTIC ENANTIOSELECTIVE SILYLATIONS OF SUBSTRATES | NATIONAL INSTITUTES OF HEALTH, U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, U.S. GOVERNMENT | 2009-12-17 | — | — | US | disclosed |
| US-20080242655-A1 | AZA-INDOLYL COMPOUNDS AND METHODS OF USE | GENENTECH, INC. | 2008-10-02 | — | — | US | disclosed |
| US-20080242655-A1 | AZA-INDOLYL COMPOUNDS AND METHODS OF USE | GENENTECH, INC. | 2008-10-02 | — | — | US | disclosed |
| US-20080085886-A1 | Anticancer and/or antiinflammatory activity, MEK (MAP kinase kinase) inhibitors; for example, 3-(2-Fluoro-4-iodo-phenylamino)-furo[3,2-c]pyridine-2-carboxylic acid ((R)-2,3-dihydroxy-propoxy)-amide | GENENTECH, INC. | 2008-04-10 | — | — | US | disclosed |
| US-20080085886-A1 | Anticancer and/or antiinflammatory activity, MEK (MAP kinase kinase) inhibitors; for example, 3-(2-Fluoro-4-iodo-phenylamino)-furo[3,2-c]pyridine-2-carboxylic acid ((R)-2,3-dihydroxy-propoxy)-amide | GENENTECH, INC. | 2008-04-10 | — | — | US | disclosed |
| US-20080081821-A1 | AZA-benzothiophenyl compounds and methods of use | GENENTECH, INC. | 2008-04-03 | — | — | US | disclosed |
| US-20080081821-A1 | AZA-benzothiophenyl compounds and methods of use | GENENTECH, INC. | 2008-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080081821-A1 | AZA-benzothiophenyl compounds and methods of use | MKI67, CDKN1A, MAP3K1 | MAPK1 4/4885LMNA 2872/4885ALDH1A1 1154/4885 |
| US-20080242655-A1 | AZA-INDOLYL COMPOUNDS AND METHODS OF USE | CDKN1A, MKI67, CCNI | MAPK1 42/4885LMNA 1746/4885ALDH1A1 1224/4885 |
| US-20090312559-A1 | CATALYTIC ENANTIOSELECTIVE SILYLATIONS OF SUBSTRATES | LSS, COASY, CYP51A1 | MAPK1 4663/4885LMNA 1731/4885ALDH1A1 836/4885 |
| US-20080085886-A1 | Anticancer and/or antiinflammatory activity, MEK (MAP kinase kinase) inhibitors; for example, 3-(2-Fluoro-4-iodo-phenylamino)-furo[3,2-c]pyridine-2-carboxylic acid ((R)-2,3-dihydroxy-propoxy)-amide | MAP3K2, MAP3K1, MAP2K2 | MAPK1 4/4885LMNA 3058/4885ALDH1A1 1140/4885 |
| US-20140248263-A1 | BISPHENOL COMPOUNDS AND METHODS FOR THEIR USE | AR, SHBG, ESRRA | MAPK1 4052/4885LMNA 611/4885ALDH1A1 438/4885 |
| US-20100216768-A1 | N-SUBSTITUTED AZAINDOLES AND METHODS OF USE | MKI67, CCNI, CDKN1A | MAPK1 13/4885LMNA 1878/4885ALDH1A1 1586/4885 |
| US-20100004269-A1 | 5-ANILINOIMIDAZOPYRIDINES AND METHODS OF USE | MKI67, MAP3K5, MAPKAPK5 | MAPK1 10/4885LMNA 1442/4885ALDH1A1 829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.